Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lymphoma was terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Marginal Zone Lymphoma
• Nodal Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Splenic Marginal Zone Lymphoma
• Testicular Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Rituximab (rituximab)
• ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Status: TERMINATED | Results posted: 2015-02-18